Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHE885 in Multiple Myeloma
NCT04318327Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label trial of durcabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Nature of Dose Limiting Toxicities at 28 days and 1 more. Started Jul 2020; status: terminated.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04318327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318327.